Profile image
Story Views

Last Hour:
Last 24 Hours:

Parkinson’s Disease Research Forecast, Analysis and Supply Demand Report 2020

Thursday, October 13, 2016 1:09
% of readers think this story is Fact. Add your two cents.

Parkinson’s Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, affecting around 7.4 million people worldwide. It is caused by the progressive loss of dopamine-producing neurons in the substantia nigra within the basal ganglia.

Browse more detail information about Parkinson’s Disease Market:

The main motor symptoms are tremors, bradykinesia and rigidity, although symptoms vary between individuals. As the disease progresses to more advanced stages, increasing symptoms and complications develop, which can cause severe disability in patients.

Get a PDF Sample of Parkinson’s Disease Market:


Scope of Parkinson’s Disease Market:

PD is a crowded market with many neuromodulatory drug classes available. However, a disease-modifying therapy with neuroprotective effects is yet to be developed.

- What are the primary mechanisms that are thought to contribute to neuronal death?

- What are the major barriers facing the development of investigational neuroprotective candidates?

Analysis reveals a high level of innovation and diversity in the pipeline, with 121 first-in-class programs acting on 57 unique molecular targets.

Neuromodulatory targets remain the dominant target family, particularly in the late-stage pipeline.

- What are the first-in-class families with a significant presence?

- How well do they align with the underlying pathways governing neuronal death in PD?

Some of the first-in-class targets have a potentially stronger chance of being translated into novel treatments for PD.

- What is the scientific rationale behind these targets? How do they perform in Preclinical studies?

- What are the commonly used disease models and the parameters measuring neuroprotective effects in PD animal studies?

Deals involving first-in-class PD products are more likely to be made in earlier stages of development than non-first-in-class deals.

- What is the dominant molecular target in the PD deals landscape?

- What are the promising first-in-class products still available for future licensing?


Reasons to buy Parkinson’s Disease Market:

This report will allow you to -

- Understand the current clinical and commercial landscape by considering the proposed pathogenic processes underlying PD neurodegeneration, diagnosis, prognosis, and the available treatment options and their usage in early and advanced PD.

- Visualize the composition of the PD market to highlight the current unmet needs in order to gain a competitive understanding of the key opportunities.

- Analyze the PD pipeline and stratify by stage of development, molecule type, and molecular target – the diversity of molecular targets in the pipeline is extremely encouraging due to the multifaceted nature of PD.

- Assess the therapeutic potential of first-in-class targets using a proprietary matrix that assesses and ranks first-in-class products according to clinical potential.

- Target the most promising and innovative PD products for early-stage investment by analyzing trends in licensing and co-development deals and accessing a curated list of first-in-class therapies potentially open to deal-making opportunities.


Have any query? ask our expert @


List of Figures, Tables and Charts Available in Frontier Pharma: Parkinson’s Disease – Identifying and Commercializing First-in-Class Innovation

1.1 List of Tables

Table 1: Definition of the Stages of Disability in Hoehn and Yahr Scale, 1967 20

Table 2: Evaluation of Disability by Unified Parkinson Disease Rating Scale, 2013 211.2 List of Figures

Figure 1: Innovation Trends in Product Approvals, 1987-2013 5

Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013 7

Figure 3: Indirect and Direct Pathways in Basal Ganglia 14

Figure 4: Molecular Targets of Marketed Products 27

Figure 5: Treatment Algorithm of Parkinson’s Disease 28

Figure 6: Efficacy and Safety of Treatments for Early Parkinson’s Disease 30

Figure 7: Efficacy and Safety of Treatments for Advanced Parkinson’s Disease 32

Figure 8: Efficacy and Safety of Treatment for Non-Motor Symptoms in Parkinson’s Disease 33

Figure 9: Developmental Pipeline Overview 36

Figure 10: Parkinson’s Disease Pipeline by Molecular Target 37

Figure 11: Parkinson’s Disease Pipeline by Molecular Target 39

Figure 12: Molecular Target Category Comparison, Pipeline and Marketed Products 40

Figure 13: Molecular Target Category Comparison, Pipeline First-in-Class and Established Molecular Targets 42

Get Discount on Parkinson’s Disease Market:

About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market dedicated towards bringing you an ingenious concoction of data parameters.

Mr. Ameya Pingaley

Absolute Reports
+1-408 520 9750
Get more market research related news @        


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.